Company intelligence / Profile preview

Genavent

Vancouver, British Columbia, Canada

Ownership: Private
Employees: ~48
Development stage: Other

Overview

Genevant is a technology-focused nucleic acid delivery company that does not develop its own therapeutics but rather licenses its platforms to pharmaceutical and biotech partners. The company's LNP technology has been used in various RNA-based therapeutics including COVID-19 vaccines.

Modalities: mRNA-based drugsSmall interfering RNALipid nanoparticle delivery therapyGene therapyAntisense oligonucleotide
Industry: Drug Discovery Services

Partnerships

Editas MedicineEpitopeaRepair BiotechnologiesKorro BioGritstone bio

Beyond the preview

Go deeper on Genavent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genavent.

Explore the full profile